TNFRSF4 and chronic myelogenous leukemia, BCR-ABL1 positive: OX-40 is highly expressed on Tregs in AML (60) and CML (30) and is currently studied as a treatment for patients with refractory/relapsed AML as monotherapy or in combination with azacitidine and avelumab (NCT03390296).